Dr. Kallmeyer is the Founder and Managing Partner of Equity4Health LLC, an early stage healthcare venture fund and of Veritas Venture Partners, which pooled interests with Earlybird in 1999.
She is also a Consulting Professor in the Department of Neurosurgery of Stanford Medical School, where she teaches courses on biomedical innovation and entrepreneurship. Formerly, she was Chief Financial Officer and Vice President of Corporate Development at Aviron (now Medimmune), a vaccine company, which she took public. In addition, she has experience in investment banking with Wasserstein Perella & Company and Flemings as well as medical training in neurosurgery and cardiology. She attended Harvard Medical School and the Royal Postgraduate Medical School in London and holds MD and PhD degrees from the Friedrich Alexander University in Erlangen, Germany. She also received an MBA degree from Stanford University. Dr. Kallmeyer serves or has served on the boards of several companies, including Entelos, Calypso Medical Technologies, and Novasonics (now Zonare). She also served on the boards of Redeon (now Biovalve), Neurovir (now Medigene), and iScribe (now Advanced PCS) until their respective acquisitions. In addition, she serves on the Board of Visitors and Scientific Advisory Board of UC Davis Medical School. She is also active in the academic, venture and start-up communities of Silicon Valley serving as a mentor to students and entrepreneurs. In this role she serves on the advisory board of START, a non-profit organization fostering entrepreneurship at European universities. She is an advisor to and frequent guest speaker at healthcare conferences both in the US and in Europe. Of particular interest to her are issues related to international venture capital, ethics related to new inventions in the biomedical field and the convergence of biology, material sciences and information technologies.
